A BILL 
To support endemic fungal disease research, incentivize 
fungal vaccine development, discover new antifungal 
therapies and diagnostics, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE; TABLE OF CONTENTS. 
3
(a) IN GENERAL.—This Act may be cited as the 
4
‘‘Finding Orphan-disease Remedies With Antifungal Re-
5
search and Development Act of 2019’’ or the ‘‘FOR-
6
WARD Act of 2019’’. 
7
(b) TABLE OF CONTENTS.—The table of contents for 
8
this Act is as follows: 
9
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
2 
•HR 2858 IH
Sec. 1. Short title; table of contents. 
Sec. 2. Continuing support for research on endemic fungal diseases. 
Sec. 3. Endemic fungal disease Federal-State match pilot program. 
Sec. 4. FDA guidance for industry on development of diagnostics and antifun-
gal drugs and vaccines for Valley Fever. 
Sec. 5. Priority review; fast track product. 
Sec. 6. Priority review vouchers for products for prevention or treatment of en-
demic fungal diseases. 
Sec. 7. Establishment of antifungal resistance research program modeled on the 
CARB–X program. 
Sec. 8. Blockchain pilot program for hospital data security for endemic fungal 
disease research. 
SEC. 2. CONTINUING SUPPORT FOR RESEARCH ON EN-
1
DEMIC FUNGAL DISEASES. 
2
The Public Health Service Act is amended by insert-
3
ing after section 320A of such Act (42 U.S.C. 247d–8) 
4
the following new section: 
5
‘‘SEC. 320B. ENDEMIC FUNGAL DISEASES. 
6
‘‘(a) IN GENERAL.—The Secretary shall continue to 
7
conduct or support epidemiological, basic, translational, 
8
and clinical research related to endemic fungal diseases, 
9
including coccidioidomycosis (commonly known as and re-
10
ferred to in this section as ‘Valley Fever’). 
11
‘‘(b) REPORTS.—The Secretary shall ensure that 
12
each triennial report under section 403 includes informa-
13
tion on actions undertaken by the National Institutes of 
14
Health to carry out subsection (a) with respect to endemic 
15
fungal diseases, including Valley Fever. 
16
‘‘(c) 
ENDEMIC
FUNGAL
DISEASE
WORKING 
17
GROUP.— 
18
‘‘(1) ESTABLISHMENT.—The Secretary shall es-
19
tablish a working group, to be known as the En-
20
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
3 
•HR 2858 IH
demic Fungal Disease Working Group (referred to 
1
in this section as the ‘Working Group’), comprised 
2
of representatives of appropriate Federal agencies 
3
and other non-Federal entities— 
4
‘‘(A) to provide expertise and to review all 
5
efforts within the Department of Health and 
6
Human Services related to endemic fungal dis-
7
ease; 
8
‘‘(B) to help ensure interagency coordina-
9
tion and minimize overlap with respect to such 
10
disease; and 
11
‘‘(C) to examine research priorities with re-
12
spect to such disease. 
13
‘‘(2) RESPONSIBILITIES.—The Working Group 
14
shall— 
15
‘‘(A) not later than 2 years after the date 
16
of enactment of the FORWARD Act of 2019, 
17
develop or update a summary of— 
18
‘‘(i) ongoing endemic fungal disease 
19
research, including research related to 
20
causes, prevention, treatment, surveillance, 
21
diagnosis, diagnostics, duration of illness, 
22
and intervention for individuals with an 
23
endemic fungal disease; 
24
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
4 
•HR 2858 IH
‘‘(ii) advances made pursuant to such 
1
research; 
2
‘‘(iii) Federal activities related to en-
3
demic fungal disease, including— 
4
‘‘(I) epidemiological activities re-
5
lated to endemic fungal disease; and 
6
‘‘(II) basic, clinical, and transla-
7
tional endemic fungal disease research 
8
related to the pathogenesis, preven-
9
tion, diagnosis, and treatment of en-
10
demic fungal disease; 
11
‘‘(iv) gaps in endemic fungal disease 
12
research described in clause (iii)(II); 
13
‘‘(v) the Working Group’s meetings 
14
required under paragraph (4); and 
15
‘‘(vi) the comments received by the 
16
Working Group; 
17
‘‘(B) make recommendations to the Sec-
18
retary regarding any appropriate changes or 
19
improvements to such activities and research; 
20
and 
21
‘‘(C) solicit input from States, localities, 
22
and nongovernmental entities, including organi-
23
zations representing patients, health care pro-
24
viders, researchers, and industry regarding sci-
25
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
5 
•HR 2858 IH
entific advances, research questions, and sur-
1
veillance activities. 
2
‘‘(3) MEMBERSHIP.—The members of the 
3
Working Group shall represent a diversity of sci-
4
entific disciplines and views and shall be composed 
5
of the following members: 
6
‘‘(A) FEDERAL MEMBERS.—Seven Federal 
7
members, consisting of one or more representa-
8
tives of each of the following: 
9
‘‘(i) The Office of the Assistant Sec-
10
retary for Health. 
11
‘‘(ii) The Food and Drug Administra-
12
tion. 
13
‘‘(iii) The Centers for Disease Control 
14
and Prevention. 
15
‘‘(iv) The National Institutes of 
16
Health. 
17
‘‘(v) Such other agencies and offices 
18
of the Department of Health and Human 
19
Services as the Secretary determines ap-
20
propriate. 
21
‘‘(B) NON-FEDERAL PUBLIC MEMBERS.— 
22
Seven non-Federal public members, consisting 
23
of representatives of the following categories: 
24
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
6 
•HR 2858 IH
‘‘(i) Physicians and other medical pro-
1
viders with experience in diagnosing and 
2
treating endemic fungal disease. 
3
‘‘(ii) Scientists or researchers with ex-
4
pertise. 
5
‘‘(iii) Patients and their family mem-
6
bers. 
7
‘‘(iv) Nonprofit organizations that ad-
8
vocate for patients with respect to endemic 
9
fungal disease. 
10
‘‘(v) Other individuals whose expertise 
11
is determined by the Secretary to be bene-
12
ficial to the functioning of the Working 
13
Group. 
14
‘‘(4) MEETINGS.—The Working Group shall 
15
meet annually. 
16
‘‘(5) REPORTING.—Not later than 2 years after 
17
the date of enactment of the FORWARD Act of 
18
2019, and every 2 years thereafter until termination 
19
of the Working Group pursuant to paragraph (7), 
20
the Working Group shall— 
21
‘‘(A) submit a report on its activities under 
22
paragraph (2)(A) and any recommendations 
23
under paragraph (2)(B) to the Secretary, the 
24
Committee on Energy and Commerce of the 
25
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
7 
•HR 2858 IH
House of Representatives, and the Committee 
1
on Health, Education, Labor, and Pensions of 
2
the Senate; and 
3
‘‘(B) make such report publicly available 
4
on the internet website of the Department of 
5
Health and Human Services. 
6
‘‘(6) APPLICABILITY OF FACA.—The Working 
7
Group shall be treated as an advisory committee 
8
subject to the Federal Advisory Committee Act (5 
9
U.S.C. App.). 
10
‘‘(7) SUNSET.—The Working Group under this 
11
section shall terminate 5 years after the date of en-
12
actment of the FORWARD Act of 2019. 
13
‘‘(d) ENDEMIC FUNGAL DISEASE DEFINED.—In this 
14
section, the term ‘endemic fungal disease’ means blasto-
15
mycosis, coccidioidomycosis, histoplasmosis, and sporotri-
16
chosis.’’. 
17
SEC. 
3. 
ENDEMIC 
FUNGAL 
DISEASE 
FEDERAL-STATE 
18
MATCH PILOT PROGRAM. 
19
(a) IN GENERAL.— 
20
(1) GRANTS.—For each of fiscal years 2021 
21
through 2025, the Secretary of Health and Human 
22
Services shall, subject to the availability of appro-
23
priations, award grants through a competitive proc-
24
ess to eligible entities to conduct research with re-
25
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
8 
•HR 2858 IH
spect to endemic fungal diseases, including coccidioi-
1
domycosis. 
2
(2) PEER
REVIEW.—Any research supported 
3
under this section shall be subject to peer review in 
4
accordance with the requirements applicable to re-
5
search supported by the National Institutes of 
6
Health under section 492 of the Public Health Serv-
7
ice Act (42 U.S.C. 289a). 
8
(b) ELIGIBILITY.—An entity eligible to receive a 
9
grant under this section is a State or local public hospital, 
10
an institution of higher education (as defined in section 
11
101 of the Higher Education Act of 1965 (20 U.S.C. 
12
1001)), a public health department, or a nonprofit organi-
13
zation that has been provided funds from State or local 
14
government sources for epidemiological, basic, translation-
15
al, and clinical research on endemic fungal diseases. 
16
(c) APPLICATION.—An entity seeking a grant under 
17
this section shall submit an application to the Secretary— 
18
(1) in such form and manner as the Secretary 
19
shall prescribe; 
20
(2) that contains a certification that the entity 
21
has received the funds described in subsection (b) 
22
and that specifies the amount of such funds; and 
23
(3) that contains such other information as the 
24
Secretary may require. 
25
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
9 
•HR 2858 IH
(d) AMOUNT OF GRANT.—The amount of a grant 
1
under this section shall equal (to the extent practicable) 
2
the amount of funds received from State or local govern-
3
ment sources for the research that is the subject of the 
4
grant. 
5
(e) ENDEMIC FUNGAL DISEASE DEFINED.—In this 
6
section, the term ‘‘endemic fungal disease’’ means blasto-
7
mycosis, coccidioidomycosis, histoplasmosis, and sporotri-
8
chosis. 
9
(f) AUTHORIZATION OF APPROPRIATIONS.—There is 
10
authorized to be appropriated to carry out this section 
11
$8,000,000 for each of fiscal years 2021 through 2025, 
12
to remain available until expended. 
13
(g) SUNSET.—The Secretary may not award grants 
14
under this section on or after October 1, 2025. 
15
SEC. 4. FDA GUIDANCE FOR INDUSTRY ON DEVELOPMENT 
16
OF DIAGNOSTICS AND ANTIFUNGAL DRUGS 
17
AND VACCINES FOR VALLEY FEVER. 
18
(a) DRAFT GUIDANCE.—Not later than 2 years after 
19
the date of the enactment of this Act, the Secretary of 
20
Health and Human Services, acting through the Commis-
21
sioner of Food and Drugs, shall issue draft guidance for 
22
industry for the purposes of assisting entities seeking ap-
23
proval under the Federal Food, Drug, and Cosmetic Act 
24
(21 U.S.C. 301 et seq.) or licensure under section 351 
25
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
10 
•HR 2858 IH
of the Public Health Service Act (42 U.S.C. 262) of 
1
antifungal therapies, diagnostics, or vaccines, specifically 
2
therapies, diagnostics, and vaccines designed to diagnose, 
3
treat, or prevent coccidioidomycosis (commonly known as 
4
Valley Fever). 
5
(b) FINAL GUIDANCE.—Not later than 18 months 
6
after the close of the public comment period on the draft 
7
guidance issued pursuant to subsection (a), the Secretary 
8
of Health and Human Services, acting through the Com-
9
missioner of Food and Drugs, shall finalize the draft guid-
10
ance. 
11
(c) WORKSHOPS; GOOD GUIDANCE PRACTICES.—In 
12
developing and issuing the guidance required by this sec-
13
tion, the Secretary of Health and Human Services shall 
14
hold at least 2 public workshops. 
15
SEC. 5. PRIORITY REVIEW; FAST TRACK PRODUCT. 
16
(a) PRIORITY REVIEW.— 
17
(1) IN GENERAL.—Section 524A(a) of the Fed-
18
eral Food, Drug, and Cosmetic Act (21 U.S.C. 
19
360n–1(a)) is amended by striking ‘‘then the Sec-
20
retary shall give priority review to the first applica-
21
tion submitted for approval for such drug under sec-
22
tion 505(b)’’ and inserting ‘‘or if the drug is a bio-
23
logical product intended to treat blastomycosis, coc-
24
cidioidomycosis, histoplasmosis, or sporotrichosis, 
25
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
11 
•HR 2858 IH
then the Secretary shall give priority review to the 
1
first application submitted for approval for such 
2
drug under section 505(b) of this Act or section 
3
351(a) of the Public Health Service Act’’. 
4
(2) APPLICABILITY.—The amendment made by 
5
paragraph (1) applies to an application submitted 
6
under section 351(a) of the Public Health Service 
7
Act (42 U.S.C. 262(a)) only if such application is 
8
submitted on or after the date of enactment of this 
9
Act. 
10
(b) FAST TRACK PRODUCT.—Section 506(b)(1) of 
11
the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 
12
356(b)(1)) is amended by striking ‘‘or if the Secretary 
13
designates the drug as a qualified infectious disease prod-
14
uct under section 505E(d)’’ and inserting ‘‘if the Sec-
15
retary designates the drug as a qualified infectious disease 
16
product under section 505E(d), or if the drug is a biologi-
17
cal product intended to treat blastomycosis, coccidioidomy-
18
cosis, histoplasmosis, or sporotrichosis’’. 
19
SEC. 6. PRIORITY REVIEW VOUCHERS FOR PRODUCTS FOR 
20
PREVENTION OR TREATMENT OF ENDEMIC 
21
FUNGAL DISEASES. 
22
Section 524(a)(3) of the Federal Food, Drug, and 
23
Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended— 
24
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
12 
•HR 2858 IH
(1) by redesignating subparagraph (S) as sub-
1
paragraph (T); and 
2
(2) by inserting after subparagraph (R) the fol-
3
lowing: 
4
‘‘(S) 
Blastomycosis, 
coccidioidomycosis, 
5
histoplasmosis, and sporotrichosis.’’. 
6
SEC. 7. ESTABLISHMENT OF ANTIFUNGAL RESISTANCE RE-
7
SEARCH PROGRAM MODELED ON THE CARB– 
8
X PROGRAM. 
9
(a) IN GENERAL.—The Secretary of Health and 
10
Human Services, acting through the Director of the Bio-
11
medical Advanced Research and Development Authority, 
12
shall carry out a program, modeled on the Combating An-
13
tibiotic Resistant Bacteria Accelerator program of the De-
14
partment of Health and Human Services (commonly re-
15
ferred to as ‘‘CARB–X’’), for research with respect to 
16
antifungal resistance, including therapies, diagnostics, and 
17
vaccines, including for coccidioidomycosis. 
18
(b) AUTHORIZATION OF APPROPRIATIONS.—There is 
19
authorized to be appropriated to carry out subsection (a) 
20
$10,000,000 for each of fiscal years 2021 through 2025, 
21
to remain available until expended. 
22
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
13 
•HR 2858 IH
SEC. 8. BLOCKCHAIN PILOT PROGRAM FOR HOSPITAL 
1
DATA SECURITY FOR ENDEMIC FUNGAL DIS-
2
EASE RESEARCH. 
3
Part A of title IV of the Public Health Service Act 
4
(42 U.S.C. 281 et seq.) is amended by adding at the end 
5
the following new section: 
6
‘‘SEC. 404O. BLOCKCHAIN PILOT PROGRAM FOR HOSPITAL 
7
DATA SECURITY FOR ENDEMIC FUNGAL DIS-
8
EASE RESEARCH. 
9
‘‘(a) IN GENERAL.—The Director of NIH shall carry 
10
out a pilot program to conduct, support, and facilitate 
11
auditable research on endemic fungal disease. In carrying 
12
out such program, the Director of NIH shall— 
13
‘‘(1) award a grant to an eligible entity to in-
14
stall a blockchain on the servers of, or otherwise pro-
15
vide blockchain services to, the National Institutes of 
16
Health, and provide support with respect to such a 
17
blockchain, which shall contain public, unalterable 
18
data which includes every query made through the 
19
procedure established under subsection (c), as well 
20
as the identity of the individual who asked such a 
21
question, without disclosing the results of such que-
22
ries; 
23
‘‘(2) award a grant to an eligible entity— 
24
‘‘(A) to provide to not less than 3 qualified 
25
hospitals qualified software; and 
26
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
14 
•HR 2858 IH
‘‘(B) to provide customer service to each 
1
such hospital with respect to such qualified 
2
software or any associated service; 
3
‘‘(3) provide to such qualified hospitals any nec-
4
essary hardware in accordance with subsection (e); 
5
and 
6
‘‘(4) award grants to eligible entities to test the 
7
cybersecurity of such qualified hospitals by attempt-
8
ing to attack simulated data on the servers of such 
9
hospitals. 
10
‘‘(b) ELIGIBLE ENTITIES; APPLICATION.—The Di-
11
rector of NIH shall determine whether an entity is eligible 
12
to receive a grant under this section and shall select hos-
13
pitals to be qualified hospitals for purposes of this section. 
14
An entity seeking a grant under this section, and a hos-
15
pital seeking to be so selected, shall submit to the Director 
16
of NIH an application in such form and manner and con-
17
taining such information as the Director of NIH may 
18
specify. 
19
‘‘(c) DATA QUERIES.—The Director of NIH shall es-
20
tablish, for purposes of allowing researchers to process 
21
data from a qualified hospital’s servers pursuant to this 
22
section, a procedure to determine— 
23
‘‘(1) who can ask queries of the servers; 
24
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
15 
•HR 2858 IH
‘‘(2) which data the hospital must include on 
1
such servers; and 
2
‘‘(3) which questions may be asked of such 
3
servers, and what form of de-identification of the 
4
servers’ data is required to ensure privacy. 
5
‘‘(d) REQUEST FOR PROPOSALS.—Not later than 90 
6
days after the date of the enactment of this section, the 
7
Director of NIH shall publish in the Federal Register a 
8
request for proposals for grants under paragraphs (1), (2), 
9
and (4) of subsection (a). 
10
‘‘(e) PROVISION OF SERVERS.— 
11
‘‘(1) IN GENERAL.—The Director of NIH shall, 
12
in carrying out subsection (a)(3), provide to quali-
13
fied hospitals hardware, including computer servers, 
14
sufficient to support qualified software. 
15
‘‘(2) CONDITION.—As a condition on the receipt 
16
of a computer server under paragraph (1), a quali-
17
fied hospital shall agree not to use the qualified soft-
18
ware on the server to store data from patients of the 
19
hospital until the Director of NIH determines that 
20
testing performed pursuant to subsection (a)(4) has 
21
determined that simulated data used in such soft-
22
ware could not be extracted from the hospital’s serv-
23
ers. 
24
‘‘(f) DEFINITIONS.—In this section: 
25
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
16 
•HR 2858 IH
‘‘(1) The term ‘blockchain’ means software that 
1
uses a distributed digital ledger of cryptographically 
2
signed transactions that are grouped into blocks, 
3
each of which— 
4
‘‘(A) is cryptographically linked to the pre-
5
vious block after validation and undergoing a 
6
consensus decision; and 
7
‘‘(B) when added as a new block, makes 
8
any older blocks more difficult to modify and is 
9
replicated across all copies of the ledger within 
10
the relevant network, with any conflicts in such 
11
blocks resolved automatically using established 
12
rules. 
13
‘‘(2) The term ‘endemic fungal disease’ means 
14
blastomycosis, 
coccidioidomycosis, 
histoplasmosis, 
15
and sporotrichosis. 
16
‘‘(3) The term ‘qualified hospital’ means a hos-
17
pital that is located in a region in which endemic 
18
fungal disease is endemic. 
19
‘‘(4) The term ‘qualified software’ means soft-
20
ware that uses secure multiparty encrypted com-
21
puting to allow researchers to perform computations 
22
on encrypted data supplied by qualified hospitals. 
23
‘‘(5) The term ‘secure multiparty encrypted 
24
computing’ means a form of cryptography in which 
25
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
17 
•HR 2858 IH
parties can jointly compute a function of inputs 
1
while keeping those inputs private from each other, 
2
and from all other parties, such as multiparty homo-
3
morphic encryption, threshold encryption, and secure 
4
multiparty computation. 
5
‘‘(g) AUTHORIZATION OF APPROPRIATIONS.—There 
6
is authorized to be appropriated to carry out this section 
7
$5,000,000 for fiscal year 2021, to remain available until 
8
expended.’’. 
9
Æ 
19:13 Jun 06, 2019
H2858
khammond on DSKBBV9HB2PROD with BILLS
